Miura Partners invests in Farmadosis, a specialist in personalized medication dosing
Mallorca-based Farmadosis, specialized in personalized dosing systems (PDS) and pharmaceutical robotics, has partnered with Barcelona-based investor Miura Partners through Miura Impact Fund. The goal is to grow and consolidate its position in pharmaceutical automation and medication traceability in southern Europe. Founder Asier Zubillaga will remain in an executive role, and Joaquín González will continue as CEO. Founded in 2012, Farmadosis has revenue of around 15 million euros and solutions installed in more than 25 countries.
In 35 seconds
- Miura Partners enters Farmadosis through Miura Impact Fund and joins its shareholder base.
- Founder Asier Zubillaga will remain in an executive role and Joaquín González will continue as CEO.
- Farmadosis aims to grow in pharmaceutical automation and medication traceability in southern Europe.
IASummary generated by artificial intelligence from a story by EntreMayores. It may contain errors: the original source prevails.




Comments
Be respectful. Comments reported by several people are hidden until a moderator reviews them.
You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.